Pediatric Hodgkin Lymphoma: on the road to a 'radiotherapy-free' cure rate?-Commentary on a report on final results of the Multinational Trial GPOH-HD95.
作者信息
Corazzelli Gaetano
机构信息
Hematology-Oncology and Stem Cell Transplantation Unit, Istituto Nazionale Tumori, Fondazione 'G. Pascale', IRCCS, Via Mariano Semmola, 80131 Naples, Italy.
出版信息
Transl Pediatr. 2013 Jul;2(3):120-3. doi: 10.3978/j.issn.2224-4336.2013.05.02.
Abstract
摘要
相似文献
1
Pediatric Hodgkin Lymphoma: on the road to a 'radiotherapy-free' cure rate?-Commentary on a report on final results of the Multinational Trial GPOH-HD95.
Transl Pediatr. 2013 Jul;2(3):120-3. doi: 10.3978/j.issn.2224-4336.2013.05.02.
2
Omitting or reducing radiotherapy in childhood or adolescence Hodgkin Lymphoma.
Transl Pediatr. 2013 Jul;2(3):126-30. doi: 10.3978/j.issn.2224-4336.2013.06.03.
3
Treatment of children and adolescents with Hodgkin lymphoma without radiotherapy for patients in complete remission after chemotherapy: final results of the multinational trial GPOH-HD95.
J Clin Oncol. 2013 Apr 20;31(12):1562-8. doi: 10.1200/JCO.2012.45.3266. Epub 2013 Mar 18.
4
The impact of central review and central therapy planning on the treatment of children and adolescents with Hodgkin lymphoma.
Eur J Cancer. 2014 Jan;50(2):425-33. doi: 10.1016/j.ejca.2013.09.017. Epub 2013 Oct 21.
5
Only strongly enhanced residual FDG uptake in early response PET (Deauville 5 or qPET ≥ 2) is prognostic in pediatric Hodgkin lymphoma: Results of the GPOH-HD2002 trial.
Pediatr Blood Cancer. 2019 Mar;66(3):e27539. doi: 10.1002/pbc.27539. Epub 2018 Nov 14.
6
Immunodeficiency and Hodgkin's disease: treatment and outcome in the DAL HD78-90 and GPOH HD95 studies.
Klin Padiatr. 2003 Nov-Dec;215(6):315-20. doi: 10.1055/s-2003-45498.
7
Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial.
Lancet Oncol. 2022 Jan;23(1):125-137. doi: 10.1016/S1470-2045(21)00470-8. Epub 2021 Dec 9.
8
Feasibility of VECOPA, a dose-intensive chemotherapy regimen for children and adolescents with intermediate and advanced stage Hodgkin lymphoma: results of the GPOH-HD-2002/VECOPA pilot trial.
Leuk Lymphoma. 2015 May;56(5):1308-14. doi: 10.3109/10428194.2014.961011. Epub 2014 Oct 9.
9
Response-adapted radiotherapy in the treatment of pediatric Hodgkin's disease: an interim report at 5 years of the German GPOH-HD 95 trial.
Int J Radiat Oncol Biol Phys. 2001 Dec 1;51(5):1209-18. doi: 10.1016/s0360-3016(01)01798-9.
10
Association between radiotherapy vs no radiotherapy based on early response to VAMP chemotherapy and survival among children with favorable-risk Hodgkin lymphoma.
JAMA. 2012 Jun 27;307(24):2609-16. doi: 10.1001/jama.2012.5847.
引用本文的文献
1
A U.S. population-based study of insurance disparities in cancer survival among adolescents and young adults.
Cancer Med. 2019 Aug;8(10):4867-4874. doi: 10.1002/cam4.2230. Epub 2019 Jun 26.
2
Treatment of Hodgkin's lymphoma in childhood and adolescence without radiotherapy.
Transl Pediatr. 2013 Jul;2(3):131-2. doi: 10.3978/j.issn.2224-4336.2013.07.02.
本文引用的文献
1
Treatment of children and adolescents with Hodgkin lymphoma without radiotherapy for patients in complete remission after chemotherapy: final results of the multinational trial GPOH-HD95.
J Clin Oncol. 2013 Apr 20;31(12):1562-8. doi: 10.1200/JCO.2012.45.3266. Epub 2013 Mar 18.
2
Interim FDG-PET in Hodgkin lymphoma: a compass for a safe navigation in clinical trials?
Blood. 2012 Dec 13;120(25):4913-20. doi: 10.1182/blood-2012-03-403790. Epub 2012 Aug 28.
3
Pediatric Hodgkin lymphoma: trade-offs between short- and long-term mortality risks.
Blood. 2012 Sep 13;120(11):2195-202. doi: 10.1182/blood-2012-02-409821. Epub 2012 Jul 23.
4
Finding the balance in pediatric Hodgkin's lymphoma.
J Clin Oncol. 2012 Sep 10;30(26):3158-9. doi: 10.1200/JCO.2012.42.6890. Epub 2012 May 29.
5
Long-term results of CCG 5942: a randomized comparison of chemotherapy with and without radiotherapy for children with Hodgkin's lymphoma--a report from the Children's Oncology Group.
J Clin Oncol. 2012 Sep 10;30(26):3174-80. doi: 10.1200/JCO.2011.41.1819. Epub 2012 May 29.
6
Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial.
Lancet. 2012 May 12;379(9828):1791-9. doi: 10.1016/S0140-6736(11)61940-5. Epub 2012 Apr 4.
7
Tumor microenvironment composition in pediatric classical Hodgkin lymphoma is modulated by age and Epstein-Barr virus infection.
Int J Cancer. 2012 Sep 1;131(5):1142-52. doi: 10.1002/ijc.27314. Epub 2011 Dec 21.
8
ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.
N Engl J Med. 2011 Jul 21;365(3):203-12. doi: 10.1056/NEJMoa1100340.
9
Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study.
Blood. 2011 Feb 10;117(6):1806-16. doi: 10.1182/blood-2010-04-278796. Epub 2010 Oct 29.
10
Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma.
N Engl J Med. 2010 Aug 12;363(7):640-52. doi: 10.1056/NEJMoa1000067.
Zotero 插件